Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IONS
  • CUSIP: 46433010
  • Web: www.ionispharma.com
Capitalization:
  • Market Cap: $6.74 billion
  • Outstanding Shares: 123,966,000
Average Prices:
  • 50 Day Moving Avg: $52.77
  • 200 Day Moving Avg: $46.68
  • 52 Week Range: $24.58 - $59.71
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -285.95
  • P/E Growth: -4.94
Sales & Book Value:
  • Annual Revenue: $420.05 million
  • Price / Sales: 16.03
  • Book Value: $1.63 per share
  • Price / Book: 33.33
Profitability:
  • EBIDTA: $33.51 million
  • Net Margins: -4.80%
  • Return on Equity: -14.61%
  • Return on Assets: -2.21%
Debt:
  • Debt-to-Equity Ratio: 2.59%
  • Current Ratio: 5.64%
  • Quick Ratio: 5.60%
Misc:
  • Average Volume: 1.38 million shs.
  • Beta: 3.15
  • Short Ratio: 10.97
 
Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.13. The company earned $110.30 million during the quarter, compared to analysts' expectations of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 14.61% and a negative net margin of 4.80%. Ionis Pharmaceuticals's revenue was up 199.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.52) EPS. View Ionis Pharmaceuticals' Earnings History.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

14 brokerages have issued 1-year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $17.00 to $65.00. On average, they expect Ionis Pharmaceuticals' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

What are analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/12/2017)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
  • 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
  • B. Lynne Parshall Esq., Chief Operating Officer, Corporate Secretary, Director
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
  • Richard S. Geary Ph.D., Senior Vice President - Development
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
  • Sarah Boyce, Chief Business Officer
  • Spencer R. Berthelsen M.D., Independent Director
  • Breaux B. Castleman, Independent Director

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BLB&B Advisors LLC (0.05%), APG Asset Management N.V. (0.05%), Creative Planning (0.02%), Sit Investment Associates Inc. (0.02%), Public Employees Retirement Association of Colorado (0.02%) and Reliance Trust Co. of Delaware (0.02%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Somerville Kurt F, Boston Advisors LLC, Bank of Montreal Can, Perkins Capital Management Inc., Sit Investment Associates Inc., Creative Planning, Reliance Trust Co. of Delaware and Capstone Asset Management Co.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Parametrica Management Ltd, Cheyne Capital Management UK LLP, Russell Investments Group Ltd., Aperio Group LLC and Public Employees Retirement Association of Colorado. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $54.33.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $44.00 (19.01% downside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Needham & Company LLCReiterated RatingBuy$64.00MediumView Rating Details
7/25/2017BMO Capital MarketsReiterated RatingOutperform$59.56 -> $62.00LowView Rating Details
7/10/2017Stifel NicolausReiterated RatingHold$42.00MediumView Rating Details
5/22/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
3/10/2017Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$28.00 -> $25.00HighView Rating Details
1/6/2017Jefferies Group LLCReiterated RatingSell$17.00N/AView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
12/27/2016LaidlawBoost Price TargetBuy$59.00 -> $65.00N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00N/AView Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
2017 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)$0.16$0.05
Q2 20172($0.38)$0.19($0.10)
Q3 20172($0.31)$0.22($0.05)
Q4 20172($0.30)$0.23($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 88.75%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.00View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.00View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.00View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.00View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.15View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.00View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.00View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.50View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.00View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.00View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.00View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.00View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.00View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.00View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.50View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.00View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
Source:
DateHeadline
americanbankingnews.com logoInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - July 26 at 10:23 PM
americanbankingnews.com logoNeedham & Company LLC Reiterates Buy Rating for Ionis Pharmaceuticals, Inc. (IONS)
www.americanbankingnews.com - July 26 at 11:59 AM
seekingalpha.com logoBiogen's Spinraza ramp fails to excite Ionis investors, shares down 8% - Seeking Alpha
seekingalpha.com - July 25 at 8:17 PM
benzinga.com logoLightning Round: Jim Cramer Gives His Opinion On Kellogg, Marriott And More - Benzinga
www.benzinga.com - July 25 at 8:17 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: SIX, PBH, IONS - Nasdaq
www.nasdaq.com - July 25 at 8:17 PM
prnewswire.com logoIonis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast - PR Newswire (press release)
www.prnewswire.com - July 25 at 8:17 PM
americanbankingnews.com logoBMO Capital Markets Reiterates "Outperform" Rating for Ionis Pharmaceuticals, Inc. (IONS)
www.americanbankingnews.com - July 25 at 5:08 PM
americanbankingnews.com logoInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Sells 11,000 Shares of Stock
www.americanbankingnews.com - July 24 at 7:28 PM
americanbankingnews.com logoIonis Pharmaceuticals, Inc. (IONS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 2:28 PM
americanbankingnews.com logoIonis Pharmaceuticals, Inc. (IONS) Major Shareholder Ionis Pharmaceuticals Inc Purchases 3,125,000 Shares
www.americanbankingnews.com - July 21 at 7:10 PM
americanbankingnews.com logoIonis Pharmaceuticals, Inc. (IONS) Expected to Announce Quarterly Sales of $83.59 Million
www.americanbankingnews.com - July 21 at 5:42 PM
finanznachrichten.de logoPro-Trader Daily: Featured Company News - Ionis Receives $10 Million Payment from Biogen
www.finanznachrichten.de - July 19 at 10:20 PM
nasdaq.com logoFeatured Company News - Ionis Receives $10 Million Payment from Biogen
www.nasdaq.com - July 19 at 10:20 PM
finance.yahoo.com logoAkcea Therapeutics Announces Closing of Initial Public Offering
finance.yahoo.com - July 19 at 10:20 PM
streetinsider.com logoIonis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB)
www.streetinsider.com - July 18 at 9:50 PM
americanbankingnews.com logoIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Sells $865,425.00 in Stock
www.americanbankingnews.com - July 18 at 7:25 PM
streetinsider.com logoIonis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB) - StreetInsider.com
www.streetinsider.com - July 18 at 2:27 AM
finance.yahoo.com logoIonis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration
finance.yahoo.com - July 18 at 2:27 AM
finance.yahoo.com logoAkcea Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - July 14 at 4:23 AM
americanbankingnews.com logoIonis Pharmaceuticals' (NASDAQ:IONS) "Outperform" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - July 12 at 11:50 AM
finance.yahoo.com logoNew Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen
finance.yahoo.com - July 11 at 5:59 AM
finance.yahoo.com logoNew Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome (FCS)
finance.yahoo.com - July 11 at 5:59 AM
seekingalpha.com logoIonis: Bullish Boost From Phase 3 Data - Seeking Alpha
seekingalpha.com - July 10 at 7:55 PM
americanbankingnews.com logoStifel Nicolaus Reiterates Hold Rating for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
www.americanbankingnews.com - July 10 at 6:36 PM
americanbankingnews.com logoTheStreet Upgrades Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to "C-"
www.americanbankingnews.com - July 7 at 2:42 PM
thestreet.com logoCommit To Purchase Ionis Pharmaceuticals At $43, Earn 14.7% Annualized Using Options - TheStreet.com
www.thestreet.com - July 7 at 6:31 AM
finance.yahoo.com logoIonis Pharamaceuticals: Will Bullish Charts and Quant Upgrade Lead to Breakout?
finance.yahoo.com - July 7 at 6:31 AM
finance.yahoo.com logoBiogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA)
finance.yahoo.com - July 4 at 4:45 PM
americanbankingnews.com logoStanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - July 3 at 7:29 PM
americanbankingnews.com logoBrett P. Monia Sells 309 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - July 3 at 7:28 PM
seekingalpha.com logoAkcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO - Seeking Alpha
seekingalpha.com - June 28 at 4:11 AM
americanbankingnews.com logoIonis Pharmaceuticals, Inc. (IONS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 27 at 12:14 PM
americanbankingnews.com logo$83.59 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter
www.americanbankingnews.com - June 25 at 10:04 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Ionis Pharmaceuticals, Inc. (IONS) to Post -$0.20 EPS
www.americanbankingnews.com - June 23 at 8:33 AM
streetinsider.com logoIonis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease - StreetInsider.com
www.streetinsider.com - June 22 at 6:07 PM
finance.yahoo.com logoETFs with exposure to Ionis Pharmaceuticals, Inc. : June 22, 2017
finance.yahoo.com - June 22 at 6:07 PM
streetinsider.com logoIonis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease
www.streetinsider.com - June 22 at 1:05 PM
finance.yahoo.com logoEnrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
finance.yahoo.com - June 22 at 1:05 PM
finance.yahoo.com logoAkcea Therapeutics Launches Proposed Initial Public Offering
finance.yahoo.com - June 20 at 6:51 PM
finance.yahoo.com logoUnderstanding Ionis Phamaceuticals’ Revenue Stream in 1Q17
finance.yahoo.com - June 14 at 7:54 PM
finance.yahoo.com logoAkcea Therapeutics’ Volanesorsen: 1Q17 Performance
finance.yahoo.com - June 13 at 10:54 AM
finance.yahoo.com logoDevelopments for Ionis Pharmaceuticals after 1Q17
finance.yahoo.com - June 13 at 10:54 AM
finance.yahoo.com logoETFs with exposure to Ionis Pharmaceuticals, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:32 PM
finance.yahoo.com logoChanges in Ionis Pharmaceuticals’ Valuation after 1Q17
finance.yahoo.com - June 9 at 8:30 PM
finance.yahoo.com logoIonis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 9:36 AM
fool.com logoWhy Ionis Pharmaceuticals Inc. Swooned 6% in May - Motley Fool
www.fool.com - June 7 at 11:30 PM
americanbankingnews.com logoIonis Pharmaceuticals Inc (IONS) Short Interest Update
www.americanbankingnews.com - June 6 at 3:46 PM
fool.com logoWhy Ionis Pharmaceuticals Inc. Swooned 6% in May
www.fool.com - June 6 at 10:25 AM
streetinsider.com logoIonis Pharma (IONS) Confirms SPINRAZA Approval in European Union; Earns $50M Milestone Payment
www.streetinsider.com - June 2 at 7:24 PM
americanbankingnews.com logoIonis Pharmaceuticals' (IONS) Buy Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - June 2 at 1:14 PM

Social

Chart

Ionis Pharmaceuticals (IONS) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff